Triple-negative breast cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-L1 26
• HER2 23
• PD-1 36
• BRCA1 5
• STAT3 1
• STING 0
• EGFR 4
• PI3K 1
• AKT 0
• BRCA2 2
• PARP 1
• TP53 1
• mTOR 0
• TROP2 6
• AR 1
• PTEN 0
• VEGF 4
• CDK4/6 3
• HIF-1 0
• MYC 0
• GPX4 0
• YAP 0
• CTNNB1 0
• JAK 1
• HDAC 0
• MAPK 0
• BCL-2 0
• CXCR4 1
• ERK 0
• NRF2 0
• PPAR 0
• B7-H3 4
• EZH2 0
• FAK 0
• PRMT5 0
• CD47 0
• HSP90 0
• PSMA 4
• IL-6 0
• PIK3CA 2
• CTLA-4 1
• HER3 2
• TNF 0
• COX-2 0
• IGF1R 0
• MEK 0
• FGFR 0
• MDM2 2
• MET 0
• MUC1 3
• NLRP3 0
• PALB2 0
• AMPK 0
• CD40 0
• CSF1R 1
• JNK 0
• METTL3 0
• MMP-9 0
• PKM2 0
• SIRT1 0

EU-13 is a filter, not a ranking: it only narrows the list.

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Updated 6 Nov 2025

  “The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

  NCT04837209· Massachusetts General Hospital· Source

• Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

  NCT03150576· Cambridge University Hospitals NHS Foundation Trust· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 45
• Organoids 9
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 108
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 32
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 49
• Liquid Biopsy 4
• Circulating Tumor DNA 16
• Xenograft Model Antitumor Assays 254
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 34
• Machine Learning 28
• Deep Learning 15
• Cohort Studies 21
• Genome-Wide Association Study 3

• NeoGen-BC: A synergistic framework combining generative protein language models and multi-window deep learning for designing shared neoantigens in breast cancer.

  Biochem Biophys Res Commun, Sept 2026

• A Deep Learning-Enabled SERS Platform for Decoding Tumor Heterogeneity and Dynamic Therapeutic Monitoring at the Cellular Level.

  ACS Sens, Aug 2026

• Deep Learning-Driven Anticancer Drug Discovery: Emodepside as a Potential Therapeutic Candidate for Triple-Negative Breast Cancer.

  J Chem Inf Model, Aug 2026

• An Explanatory Deep Learning Pipeline for the Prediction and Visualization of Spatially Resolved Biomarker Expression in Triple-Negative Breast Cancer.

  Am J Pathol, Aug 2026

• Object detection in histology: A multi-dataset benchmark and test-time inference.

  PLoS One, Jul 2026

• A multimodal deep learning classifier for prediction of HER2-low expression in triple-negative breast cancer.

  BMC Med Imaging, Jul 2026

• Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology.

  Ann Oncol, May 2026

• Evidential reasoning-enabled deep learning for reliable treatment outcome prediction in cancer therapy.

  Artif Intell Med, May 2026

• Integrating tumor habitat heterogeneity with a hybrid deep learning architecture for ultrasound radiomics: a dual-center study on non-invasive prediction of PD-L1 expression in triple-negative breast cancer.

  Breast Cancer Res, Apr 2026

• An Exploratory Study on Prognostic Prediction and Interpretability Analysis in Early-stage Triple-negative Breast Cancer Using Pathological Images.

  Biomed Environ Sci, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.